DexCom, Inc.

Jurisdiction

United States

LEI

549300YSK3QDSFR5EU59

ISIN

US2521311074

(DXCM)

Sectors

Scores

InsiderPie Expert Score: 80 / 100
Better than peer group:: 53 / 100
Fair value (Benjamin Graham formula): €60.43 5.0% undervalued
Financial strength (Piotroski F-Value): 5 / 9
Fundamental strength relative to industry (Mohanram G-Value): 6 / 7

Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. Read full profile

Fundamentals

Net revenue: €3.67B
Gross margin: 58.7%
EBIT: €586.15M
EBIT margin: 16.0%
Net income: €487.46M
Net margin: 13.3%

Statement period: July 1, 2024 - June 30, 2025 (published July 30, 2025)

Estimates

Fiscal Year	Net revenue	Net income
2026	€4.55B +24.1%	€878.96M +80.3%
2027	€5.19B +14.1%	€1.08B +22.4%
2028	€6.00B +15.6%	€1.38B +28.3%

Dividends

No dividend payouts

Analyst ratings

No analyst ratings available

Insider Transactions

Name	Title	Transaction Date	Shares	Price	Value
Stern Sadie	EVP, Chief HR Officer	September 4, 2025	-1.5K	$80.00	-$117.28K
Sylvain Jereme M	EVP, Chief Financal Officer	September 2, 2025	-4.8K	$74.17	-$357.80K
Brown Michael Jon	EVP, Chief Legal Officer	August 15, 2025	-500	$80.29	-$40.15K
FOLETTA MARK G	N/A	August 15, 2025	-2.8K	$81.06	-$222.92K
Stern Sadie	EVP, Chief HR Officer	July 28, 2025	-1.5K	$88.99	-$130.46K

Congress transactions

Name	Transaction date	Value
Jefferson Shreve	June 22, 2025	$15.00K–$50.00K
Jefferson Shreve	June 22, 2025	$15.00K–$50.00K
Robert Bresnahan	June 9, 2025	$1.00K–$15.00K
Jefferson Shreve	May 8, 2025	$15.00K–$50.00K
Robert Bresnahan	April 28, 2025	$1.00K–$15.00K